These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31107542)

  • 1. Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial.
    Boige V; Mollevi C; Gourgou S; Azria D; Seitz JF; Vincent M; Bigot L; Juzyna B; Miran I; Gerard JP; Laurent-Puig P
    Int J Cancer; 2019 Dec; 145(11):3163-3172. PubMed ID: 31107542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study.
    Yang B; Shan J; Feng Y; Dai N; Li M; Chen C; He S; Wang G; Xiao H; Li C; Wang D
    Radiat Oncol; 2020 May; 15(1):94. PubMed ID: 32375814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer.
    Yang XH; Li KG; Wei JB; Wu CH; Liang SX; Mo XW; Chen JS; Tang WZ; Qu S
    Sci Rep; 2020 Jul; 10(1):12539. PubMed ID: 32719436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.
    Gérard JP; Azria D; Gourgou-Bourgade S; Martel-Lafay I; Hennequin C; Etienne PL; Vendrely V; François E; de La Roche G; Bouché O; Mirabel X; Denis B; Mineur L; Berdah JF; Mahé MA; Bécouarn Y; Dupuis O; Lledo G; Seitz JF; Bedenne L; Juzyna B; Conroy T
    J Clin Oncol; 2012 Dec; 30(36):4558-65. PubMed ID: 23109696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Genetic variations in MLH3 and MSH2 genes are associated with the sensitivity and prognosis in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy].
    Yang J; Wang X; Zou SM; Li HM; Xiao Q; Feng YR; Huang Y; Feng T; Chen JN; Lin DX; Li YX; Jin J; Tan W
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):433-440. PubMed ID: 29936769
    [No Abstract]   [Full Text] [Related]  

  • 6. [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
    Qiao Y; Ren H; Huang Y; DU ZL; Yu DK; Jin J; Li YX; Lin DX; Tan W
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):268-72. PubMed ID: 23985254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer.
    Larsen FO; Markussen A; Jensen BV; Fromm AL; Vistisen KK; Parner VK; Linnemann D; Hansen RH; Johannesen HH; Schou JV
    Clin Colorectal Cancer; 2017 Jun; 16(2):e7-e14. PubMed ID: 27743742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases.
    Cho H; Kim JE; Kim KP; Yu CS; Kim JC; Kim JH; Lee MA; Jang HS; Oh ST; Kim SY; Oh JH; Kim DY; Hong YS; Kim TW
    Am J Clin Oncol; 2016 Dec; 39(6):623-629. PubMed ID: 27322695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.
    Azria D; Doyen J; Jarlier M; Martel-Lafay I; Hennequin C; Etienne P; Vendrely V; François E; de La Roche G; Bouché O; Mirabel X; Denis B; Mineur L; Berdah J; Mahé M; Bécouarn Y; Dupuis O; Lledo G; Seitz J; Bedenne L; Gourgou-Bourgade S; Juzyna B; Conroy T; Gérard J
    Ann Oncol; 2017 Oct; 28(10):2436-2442. PubMed ID: 28961836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy.
    Huang MY; Huang JJ; Huang CM; Lin CH; Tsai HL; Huang CW; Chai CY; Lin CY; Wang JY
    World J Surg; 2017 Nov; 41(11):2884-2897. PubMed ID: 28608017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt.
    Formica V; Benassi M; Del Vecchio Blanco G; Doldo E; Martano L; Portarena I; Nardecchia A; Lucchetti J; Morelli C; Giudice E; Rossi P; Anselmo A; Sileri P; Sica G; Orlandi A; Santoni R; Roselli M
    Med Oncol; 2018 May; 35(6):83. PubMed ID: 29721745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer.
    Valentini V; Gambacorta MA; Cellini F; Aristei C; Coco C; Barbaro B; Alfieri S; D'Ugo D; Persiani R; Deodato F; Crucitti A; Lupattelli M; Mantello G; Navarria F; Belluco C; Buonadonna A; Boso C; Lonardi S; Caravatta L; Barba MC; Vecchio FM; Maranzano E; Genovesi D; Doglietto GB; Morganti AG; La Torre G; Pucciarelli S; De Paoli A
    Radiother Oncol; 2019 May; 134():110-118. PubMed ID: 31005204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03.
    Kim SY; Joo J; Kim TW; Hong YS; Kim JE; Hwang IG; Kim BG; Lee KW; Kim JW; Oh HS; Ahn JB; Zang DY; Kim DY; Oh JH; Baek JY
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):889-899. PubMed ID: 29976501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
    Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
    Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.
    Dreussi E; Cecchin E; Polesel J; Canzonieri V; Agostini M; Boso C; Belluco C; Buonadonna A; Lonardi S; Bergamo F; Gagno S; De Mattia E; Pucciarelli S; De Paoli A; Toffoli G
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27608007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
    Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
    Feng YR; Jin J; Ren H; Wang X; Wang SL; Wang WH; Song YW; Liu YP; Tang Y; Li N; Liu XF; Fang H; Yu ZH; Li YX
    BMC Cancer; 2017 Mar; 17(1):182. PubMed ID: 28279170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of Oxaliplatin-based Neoadjuvant Chemoradiotherapy in Elderly Locally Advanced Rectal Cancer Patients: A Case-control Study of a Real-life Experience.
    DE Felice F; Siniscalchi B; Bulzonetti N; Caiazzo R; Musio D; Tombolini V
    Anticancer Res; 2019 Dec; 39(12):6957-6963. PubMed ID: 31810967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.